Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Lung Function
- Sponsor
- Chinese University of Hong Kong
- Enrollment
- 700
- Locations
- 1
- Primary Endpoint
- 6 minute walk distance
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
(a) Objectives
- To assess the full lung function, exercise capacity, quality of life in patients with COVID-19 over 2 years.
- To assess the longevity of the serology response to SARS-CoV2.
- To investigate the association of the neutralization titer in plasma from different vaccinated cohorts to its protection of infection using in vivo model
- To investigate the SARS-CoV-2 specific cellular and humoral immunities as well as their determinant factors from community subjects who have received different types of COVID-19 vaccines.
- To assess the third booster dose for subjects who have poor antibody response despite having received two doses of CoronaVac (Sinovac)
Detailed Description
The health conditions of adults (N=300) who recovered from varying severity of COVID-19 will be assessed and their blood are collected at 6, 12, 24 and 36 months after discharge. The assessment package includes: lung function tests, 6-min walk distance, chest radiographs/CT, and SF36 General Health questionnaire. Blood samples from community cohorts will be collected from before and up to 36 months after receiving one of the three COVID-19 vaccines (N=200 per vaccine type). The kinetics of SARS-CoV-2 specific humoral and cellular immunities from both convalescent and vaccinated cohorts are determined by neutralization assay and by measuring specific T cell responses upon stimulation of SARS-CoV-2 specific peptide library respectively. The antiviral level of the human plasma with various neutralization titer collected from different vaccinated cohorts will be tested in mouse model and ADCC assay.
Investigators
Prof David Shu Cheong Hui
Professor
Chinese University of Hong Kong
Eligibility Criteria
Inclusion Criteria
- •Patients who have been discharged from hospital following treatment for COVID-19 -
Exclusion Criteria
- •Unwilling to be follow up
Outcomes
Primary Outcomes
6 minute walk distance
Time Frame: 3 years
meters
Lung volume
Time Frame: 3 years
Litres
spirometry
Time Frame: 3 years
FEV1 and FVC
Secondary Outcomes
- quality of life by SF36 questionnaire(3 years)
- serology and T cell response(3 years)